In contrast to GIP, the insulinotropic effect of GLP-1 is retained in patients with T2DM (218), and it is possible with infusions of GLP-1 to completely normalize glucose-induced insulin secretion in these patients (219,222). The gene discussed is INS; the disease is type 2 diabetes mellitus.